# A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

> **NCT06940739** · PHASE1,PHASE2 · RECRUITING · sponsor: **Iovance Biotherapeutics, Inc.** · enrollment: 42 (estimated)

## Conditions studied

- Unresectable Melanoma
- Metastatic Melanoma
- Ocular Melanoma

## Interventions

- **BIOLOGICAL:** IOV-3001

## Key facts

- **NCT ID:** NCT06940739
- **Lead sponsor:** Iovance Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2032-06
- **Final completion:** 2032-07
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940739, "A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06940739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*